Nymox Association Conventions

November 8, 2017 3:37 pm Published by 2 Comments

Nymox Pharmaceutical Corporation  is pleased to announce an important upcoming symposium and panel discussion on its first-in-class investigational drug NX-1207, currently in late stage Phase 3 for benign prostatic hyperplasia (BPH) and Phase 2 for Prostate Cancer. The symposium will be held during the 2018 Annual Meeting of the American Urological Association in San Diego CA 3:00 p.m. May 5 in the San Diego Convention Center.

Categorised in:

This post was written by nymadm


Leave a Reply

Your email address will not be published.